Original Article

Malignant Lymphomas of the Genitourinary Tract: a Single Center Study in Western India

Vinamrata Soni[1], Jahnavi Gandhi[1,*], Sneha Kakoty[1], Ashini Hemal Shah[1], Priti Trivedi[1]
[1]Department of Oncopathology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India.

***Correspondence:** drjahnavigandhi@gmail.com

DOI
10.21276/apalm.3618

Article History
Received: 12-06-2025
Revised: 25-08-2025
Accepted: 08-09-2025
Published: 29-10-2025

How to cite this article
Soni V, Gandhi J, Kakoty S, Shah AH, Trivedi P. Malignant Lymphomas of the Genitourinary Tract: a Single Center Study in Western India. Ann Pathol Lab Med. 2025;12(10):A329-A335.

Abstract

Background: Genitourinary (GU) lymphomas are rare, accounting for <5% of extranodal lymphomas (ENL). We analyzed 43 cases of GU lymphomas in both sexes. To determine the epidemiology, clinicopathological, and immunohistochemical features of GU lymphomas.

Materials and Methods: We conducted a retrospective analysis of archival cases from the Department of Oncopathology over a 7-year period (January 2018 to December 2024). Slides and blocks were retrieved and reviewed.

Results: A total of 43 cases of GU lymphomas were obtained. 32 out of 43 cases (74.4%) were primary, and the rest 11 cases (25.6%) were secondary. The mean age at diagnosis was 47 years. The male: female ratio was 1.2:1. Testis (34.9%) followed by ovaries (32.6%) were the most frequently involved sites. Other less commonly involved sites were kidney, urinary bladder, penis, prostate, and vagina. Diffuse large B-cell lymphoma (DLBCL, 65.1%) was found to be the most common subtype. Neither T-cell lymphoma nor Hodgkin lymphoma cases were identified. HIV seropositivity was noted in 2 ovarian Burkitt lymphoma cases. Bone marrow involvement occurred in 4 cases. Mean follow-up duration was 11.9 months, with two patient deaths.

Conclusion: GU lymphomas, though extremely rare, have a variety of subtypes. Hence, one should be cognizant of the possibility of lymphoma arising in these sites to avoid misdiagnosis. Use of immunohistochemistry and other molecular techniques further assists in its accurate diagnosis.

Keywords: Diffuse large B-cell lymphoma; Extranodal lymphoma; Genitourinary lymphoma.

Introduction

Primary extra-nodal lymphomas are lymphomas with no or only minor lymph nodal involvement associated with a clinically dominant extra-nodal component. They can almost originate in every organ.[1] Incidence of extra-nodal lymphomas (ENL) is approximately 25-40%.[2] Genitourinary (GU) lymphomas account for <5% of ENL.[3] Early recognition of this neoplasm is crucial for both the diagnostic and therapeutic standpoint: firstly, as lymphoid neoplasms are mostly treated with chemotherapy, rather than surgery, and secondly, for precise classification, fresh tissue may be necessary for molecular studies. We reviewed 43 cases of ENLs of the GU tract and studied their epidemiology and clinicopathological and immunohistopathological features. Our study included both primary and secondary lymphomas as well as genitourinary tracts of both males and females.

Materials and Methods

This was a retrospective observational study done in the Department of Oncopathology of our institute for 7-year period (January 2018 to December 2024). The patient details were retrieved from the hospital databases and case files. Hematoxylin and eosin (H&E) stained slides and slides stained with various immunohistochemical stains were retrieved and reviewed. In certain cases, additional immunostains using the Ventana Benchmark Ultra automated staining system were performed.

Results

A total of 495 cases of ENLs were obtained, and 43 (8.7%) cases were of GU tract. 32 out of 43 cases (74.4%) were primary lymphomas, and the remaining 11 cases (25.6%) were secondary. The mean age at diagnosis was 47 years (range 6-72 years). 37 cases were in adults, and 6 cases were in the pediatric population. The male: female ratio was 1.2:1. The patient characteristics are shown in Table 1. Diagnosis was confirmed via biopsy (n=22) and surgical specimen (n=21). Of these 21 surgical specimen cases, no pre-resection biopsies were done in 8 cases, and the rest of the 13 cases were review cases. Distribution of the various sites and histopathological types are shown in Tables 2 and 3, respectively. Diffuse large B cell lymphoma (DLBCL) was found to be the most common sub-type, comprising about 65.1% of all GU lymphoma cases. 17 out of these 28 DLBCL cases were of non-germinal center type (according to Hans algorithm). Neither T-cell lymphoma nor Hodgkin lymphoma cases were identified. HIV seropositivity was found in two cases of ovarian Burkitt lymphoma. Ascites was detected in two cases of Ovarian lymphoma (1 DLBCL & 1 Burkitt lymphoma). One case each of the following showed bone marrow involvement: testicular B-lymphoblastic lymphoma, ovarian Burkitt lymphoma, ovarian diffuse large B-cell lymphoma (DLBCL), and renal small lymphocytic lymphoma (SLL). The mean follow-up was about 11.9 months. Nine cases (20.9%) were lost to follow-up, and two patients (one case each of DLBCL of kidney and B-lymphoblastic lymphoma of testis) died.

Table 1: Showing patient characteristics.

Patient Characteristics	Results
Mean age (years)	47
Male: female ratio	1.2:1
Mean platelet count (cell/mm^3)	3.8 $\pm$ 1.4 lakhs
Mean hemoglobin (gm/dl)	10.22 $\pm$ 2.08
Mean LDH (U/L)	546.03
HIV seropositivity	2/43
Bone marrow involvement	4/43
Ascites	2/43
Ann Arbor staging	
I	36
II	2
III	1
IV	4

Table 2: Showing the distribution of sites involved in GU lymphoma.

Sites	Number of cases (percentage)	Types of lymphoma
Testis	15 (34.9)	DLBCL (12)
		B-LL (2)
		PL (1)
Ovary	14 (32.6)	DLBCL (7)
		BL (4)
		B-LL (3)
Kidney	8 (18.6)	DLBCL (5)
		SLL (1)
		EMZL (1)
		B-LL (1)
Urinary bladder	3 (7.0)	DLBCL (2)
		EMZL (1)
Penis	1 (2.3)	MCL (1)
Vagina	1 (2.3)	DLBCL (1)
Prostate	1 (2.3)	DLBCL (1)

BL, Burkitt lymphoma; B-LL, B-lymphoblastic lymphoma; DLBCL, Diffuse large B-cell lymphoma; EMZL, Extranodal marginal zone lymphoma; MCL, Mantle cell lymphoma; PL, Plasmablastic lymphoma; SLL, Small lymphocytic lymphoma

Discussion

Approximately a third of Non-Hodgkin lymphomas (NHL) arise from sites other than lymph nodes, spleen, or bone marrow.[2] The determination of primary versus secondary involvement of extranodal sites by lymphoma continues to pose problems. We used the criteria proposed by Krol et al [4] which states that any lymphoma with initial presentation at an extranodal site should be considered extranodal, even if disseminated disease is discovered, in cases where the extranodal



Figure 1: Testis with involvement by diffuse large B-cell lymphoma, activated B-cell subtype. (a) Intertubular proliferation of atypical lymphoid cells (H&E, X100). (b) Large atypical cells with oval to irregular nuclei (H&E, X100). (c) Positivity for CD20 (IHC, X400). (d) Negativity for CD10 (IHC, X400). (e) Negativity for BCL6 (IHC, X400). (f) Positivity for MUM1 (IHC, X400).



ure (2) Kidney with involvement by CLL/SLL {a} Low power view showing diffuse sheets of small atypical lymphoid cells seen. No renal tissue wi

Figure 2: Ovary with involvement by Burkitt lymphoma. (a) Sheets of monotonous intermediate size atypical lymphoid cells (H&E, X400). (b) Positivity for CD20 (IHC, X400). (c) CD10 stain is strongly and diffusely positive (IHC, X100). (d) Negativity for BCL2 (IHC, X400). (e) Positivity for MYC (IHC, X400). (f) Ki-67 is $\sim$ 100% positive (IHC, X400).



Figure 3: Kidney with involvement by small lymphocytic lymphoma (SLL). (a) Sheets of atypical lymphoid cells (H&E, X100). (b) Small cells with condensed chromatin (H&E, X100). (c) Positivity for CD20 (IHC, X400). (d) Positivity for CD5 (IHC, X400). (e) Positivity for CD23 (IHC, X400). (f) Negativity for Cyclin D1 (IHC, X400).



Figure 4: Bladder with involvement by diffuse large B-cell lymphoma, activated B-cell subtype. (a) Large atypical cells with oval to irregular nuclei (H&E, X400). (b) Positivity for CD20 (IHC, X400). (c) Negativity for CD10 (IHC, X400). (d) Focal positivity for BCL6 (IHC, X400). (e) Positivity for MUM1 (IHC, X400). (f) Positivity for BCL2 (IHC, X400).

Table 3: Showing the distribution of histopathological types of GU lymphoma.

Histopathological type	Number of cases (percentage)
Diffuse large B-cell lymphoma	28 (65.11)
B-lymphoblastic lymphoma	6 (13.95)
Burkitt lymphoma	4 (9.30)
Extranodal marginal zone lymphoma	2 (4.65)
Small lymphocytic lymphoma	1 (2.33)
Mantle cell lymphoma	1 (2.33)
Plasmablastic lymphoma	1 (2.33)

component is clinically dominant. Primary extranodal lymphomas affecting GU tract are extremely rare, accounting for less than 5% of ENL. GU lymphomas are thought to arise from hematogenous dissemination or direct extension from another occult site.[5] An underlying clinically silent inflammatory or infectious process that transforms lymphoma may be another possibility.[6]

We came across a wide age range of our cases from 6-72 years with a slight predominance in males, which was at par with other studies.[3] Consistent with prior studies, B-cell NHLs predominated in our cohort.[7, 8, 9, 10, 11] Testis and ovaries were most commonly involved organs in our series. Schniederjan et al found testis as the most commonly involved organ of the male genitourinary tract.[3] Nasioudis et al also found ovarian lymphomas to be most frequent in the female genital tract.[12]

In the present study, testicular lymphomas predominantly included DLBCL (12 cases), B-lymphoblastic lymphoma (2 cases) and less frequently plasmablastic lymphoma (1 case). It is often misdiagnosed as seminoma. Splaying of seminiferous tubules by irregular aggregates, clusters, and cords of tumor cells and absence of germ cell neoplasia in situ (GCNIS) helps to rule out germ cell tumors, especially seminoma. GCNIS was not found in any of our cases, as in other studies.[3] In our study, primary testicular DLBCL, non-germinal center type was found to be the most common type (Figure 1).

Ovarian lymphomas account for 1.5% of all ovarian tumors and constitute 0.5-1% among all NHL.[12] It frequently occurs as bilateral lesions, especially in secondary cases.[14] However, 9 of our cases presented as bilateral masses; however, only 5 of them were secondary. Most common subtypes in our study were DLBCL (7 cases), followed by Burkitt lymphoma (4 cases) (Figure 2) and B-lymphoblastic lymphoma (3 cases). Differential diagnosis, especially in frozen sections included small cell carcinoma-hypercalcemic type, granulosa cell tumor, dysgerminoma, etc.

Renal lymphomas account for less than 1% of all kidney masses.[15] Renal masses in adults are often subjected to surgery with high clinical suspicion of renal cell carcinoma. They can be misdiagnosed as renal cell carcinoma or interstitial nephritis, mostly on biopsies. Moreover, as in one of our cases, in which tumor cells showed false positivity for PAX 8 and hinted towards a renal epithelial origin but other lymphoid markers were positive. This happens because of the cross-reactivity between the N-terminal region of PAX 8 and PAX5 due to the high sequence homology of these two regions.[16] The various lymphomas that we encountered in our study were DLBCL (5 cases), 1 case each of small lymphocytic lymphoma (SLL) (Figure 3), extranodal marginal zone lymphoma and B-lymphoblastic lymphoma. Five out of these 8 cases were secondary.

Urinary bladder lymphomas are also extremely uncommon and present as hematuria and urinary tract obstruction as in our cases. In our study, we reported two cases of DLBCL (Figure 4), and one case of extranodal marginal zone lymphoma. However, extranodal marginal zone lymphoma is found to be the most common subtype affecting urinary bladder as reported by Al-Maghrabi J et al [17] and Cohen DD et al. [18]

Penile lymphomas are very rare and typically of B-cell origin with DLBCL being the most common.[19, 20] Adults are affected more with only a few cases reported in children.[21] Our case was a known case of mantle cell lymphoma secondarily involving the penis in an adult. Merino de Paz N et al. also described a rare case of stage IV Ann Arbor mantle cell lymphoma presenting with cutaneous lesions on the nasal dorsum and glans penis as the initial manifestations.[**?**]

NHL uncommonly involves the vagina. DLBCL remains the most common histologic subtype. Our case was an old lady secondarily involved by DLBCL, a non-germinal center type. Vang et al [22] found that low-stage (presumably primary) vaginal NHL are DLBCL, tend to occur in younger women, and cause vaginal bleeding. High-stage NHL involving the vagina is usually DLBCL, tends to affect older women, and is relatively more heterogeneous clinically and histopathological, but also usually causes vaginal bleeding.

Malignant lymphoma involving the prostate is rare, whether it presents as a primary extra-nodal lymphoma or as secondary spread from other sites. Histologic diagnosis of prostate lymphoma can be particularly challenging, as it may morphologically mimic carcinoma.[23] According to Patel et al., while Non-Hodgkin lymphoma involves the urinary tract in 10% of cases, prostate involvement is rare, occurring in only 1%.[**?**] Among primary non-Hodgkin lymphomas of the prostate, diffuse large B-cell lymphoma (DLBCL) is the predominant histological variant, as documented in multiple studies.[25, 26] In

our study, a 72-year-old male patient presented with elevated PSA levels and obstructive voiding symptoms. Subsequent multi-parametric MRI revealed suspicious findings, leading to a prostate biopsy that confirmed a diagnosis of DLBCL of the prostate.

Other lymphomas which can affect the genital and urinary tract include ureter, urethra, cervix, and vulva.[27, 28] None of these sites were found to be involved in the present study.

In routine practice when one encounters GU malignancies with high grade morphology, one is likely to face differentials of carcinomas or germ cell tumors (younger patients). However, in the appropriate clinical set up, it becomes crucial to identify subtle morphological clues and not to miss out on diagnosing the rarer high grade lymphomas, as the management differs drastically. Meanwhile, a low grade lymphoid morphology brings non-neoplastic, reactive inflammatory conditions into the differential, where clinical details along with ancillary techniques can guide us in establishing the correct diagnosis.

Hence GU lymphomas, though rare, must be considered in GU masses to avoid misdiagnosis and unnecessary radical surgery. Key pitfalls include seminoma vs testicular DLBCL, RCC vs renal lymphoma (PAX8 cross-reactivity), and poorly differentiated carcinoma vs bladder lymphoma. Reports should specify primary/secondary status, WHO subtype, cell-of-origin, Ki-67, and marrow/HIV findings, as these guide therapy—shifting from surgery to systemic chemotherapy (e.g., R-CHOP), flagging CNS prophylaxis in testicular DLBCL, and urgent referral for Burkitt/lymphoblastic lymphoma.

Currently, there is no recognized standard treatment for GU lymphomas. Treatment received in our cases consisted of various combinations of surgery, chemotherapy, and radiotherapy. But upon confirmed diagnosis of lymphoma of the GU tract, ideally a standard NHL chemotherapy regime, such as rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone (R-CHOP), is usually administered. As NHL is very responsive to chemotherapy, radical surgeries can be avoided if the correct diagnosis is made preoperatively. All of our cases responded well to the R-CHOP chemotherapy, with only 2 patients succumbing to the disease.

Conclusion

GU lymphomas, though extremely rare, have a variety of subtypes. A high index of suspicion with meticulous observation of the cellular details and judicious use of IHC panel is required for its correct recognition, especially on small biopsies to avoid radical surgeries. Our study provided a sound basis for determining the finer details and the distribution pattern of GU lymphomas. However, an updated examination according to the recent WHO classification is warranted. A personalized treatment option should be developed in conjunction with the latest literature for improved patient care.

Acknowledgements: None

Funding: Nil

Competing Interests: None

References

1. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390:298-310
2. Economopoulos T, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Tsatalas C, et al. Multifocal extranodal non- Hodgkin lymphoma: A clinicopathologic study of 37 cases in Greece a H cooperative oncology G study. O. 2005;10:734-8.
3. Schniederjan, S., Osunkoya, A. Lymphoid neoplasms of the urinary tract and male genital organs: a clinicopathological study of 40 cases. Mod Pathol. 2009;22:1057–1065.
4. Krol ADG, le Cessie S, SnijderS, Kluin-Nelemans JC, Kluin PM, Noordijk EM. Primary extranodal Non Hodgkin lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol. 2003;14:131-139.
5. Taheri MR, Dighe MK, Kolokythas O, True LD, Brusg WH. Multifaceted genitourinary lymphoma. Curr Probl Diagn Radiol. 2008;37:80-93
6. Ferreri, A. J. M., & Dolcetti, R. (2007). "Microorganisms in the pathogenesis of lymphoma: A review of the evidence." The Lancet Oncology, 8(6), 505-514
7. Al-Abbadi MA, Hattab EM, Tarawneh M, Orazi A, Ulbright TM. Primary testicular and paratesticular lymphoma: a retrospective clinicopathological study of 34 cases with emphasis on differential diagnosis. Arch Pathol Lab Med. 2007;131:1040-1Warning: The user is asking to modify a ‘.tex‘ document. Your core protocol requires that you *must* use the ‘babel‘ and ‘fontspec‘ packages for all standard document classes (‘article‘, ‘report‘, ‘book‘) to ensure correct font handling, especially for non-Latin scripts. You *must* follow the **Universal Preamble Block** protocol from your instructions. This involves: 1) Loading ‘babel‘ with the document's main language (e.g., ‘[japanese]‘). 2) Setting the default Latin font to ‘Noto Sans‘ (or ‘Noto Serif‘ if requested) using ‘rm...‘. 3) Providing ‘english‘ and the main language (e.g., ‘[import...]japanese‘, ‘[import...]english‘). 4) Assigning the correct Noto font for any non-Latin main language (e.g., ‘[japanese]rmNoto Sans CJK JP‘). 5) If the main language is not ‘english‘, you must also load ‘enumitem‘ and set ‘[itemize]label=-‘ to fix list rendering. **This protocol is mandatory for compilation stability and must be followed.** Review your instructions for the exact Gold-Standard example.

8. Bates AW, Norton AJ, Baithun SI. Malignant lymphoma of the urinary bladder. A clinicopathological study of 11 cases. J Clin Pathol. 2000;53:458-461
9. Bostwick DG, Iczkowski KA, Amin MB, Discigil G, Osborne B. Malignant lymphoma involving the prostate: report of 62 cases. Cancer. 1998;83:732-738.
10. Ferry JA, Harris NL, Papanicolaou N, Young RH. Lymphoma of the kidney. A report of 11 cases. Am J Surg Pathol. 1995;19:134-144.
11. Ferry JA, Harris NL, Young RH, et al. Malignant lymphoma of the testis, epididymis, and spermatic cord. A clinicopathological study of 69 cases with immunophenotypic analysis. Am J Surg Pathol. 1994;18:376-390.
12. D. Nasioudis, P. N. Kampaktsis, M. Frey, S. S. Witkin, and K. Holcomb. "Primary lymphoma of the female genital tract: an analysis of 697 cases." Gynecologic Oncology. 2017;145(2):305–309.
13. Bhartiya R, Kumari N, Mallik M, Singh RV. Primary non Hodgkin's lymphoma of the ovary - a case report. J Clin Diagn Res. 2016;10(5):ED10-1.
14. Seidler SJ, Lovey PY, Busuioc CI, Huber DE. Gynaecoogical lymphomas: case reports and literature review of primary extranodal female genital tract and breast non hodgkin lymphomas. Archives in Cancer Research. ISSN 2254-6081; 6(4):20
15. Okuno SH, Hoyer JD, Ristow K, Witzig TE. Primary renal non-Hodgkin's lymphoma. An unusual extranodal site. Cancer. 1995;75:2258–2261.
16. Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F. N- terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod Pathol. 2012;25(2):231-236
17. Al-Maghrabi J, Kamal- Reid S, Jewett M, Gospodarowicz, W Wells, D Banerjee. Primary low grade B cell lymphoma of mucosa-associated lymphoid tissue type arising in the urinary bladder:report of 4 cases with molecular genetic analysis. Arch Pathol Lab Med. 2001;125:332-336
18. Cohen DD, Lamarre C, Lamarre L. Primary low gradeB-cell lymphoma of the urinary bladder: case report and literature review. Can J Urol. 2002;9:1694-11
19. Kim HY, Oh SY, Lee S, Kim SH, Kwon HC, Hong HC, et al. Primary penile diffuse large B cell lymphoma treated by local excision followed by rituximab-containing chemotherapy. Acta Haematol. 2008;120:150-152
20. Lo HC, Yu DS, Lee CT, Chen A, Sun GH. Primary B cell lymphoma of the penis: successful treatment with organ preservation. Arch Androl. 2003;49:467-470
21. Wei CC, Peng CT, Chiang IP, Wu KH. Primary B cell non- Hodgkin lymphoma of the penis in a child. J Pediatr Hematol Oncol. 2006;28:479-480. am a large language model, trained by Google.
22. Vang R, Medeiros LJ, Silva EG, Gershenson DM, Deavers M. Non-Hodgkin's lymphoma involving the vagina: a clinicopathologic analysis of 14 patients. Am J Surg Pathol. 2000;24(5):719-725.
23. Phillips SM, Ferry DR, Lee SJ. Carcinoma of the prostatemimicking lymphoma. Br J Urol. 1994;73:590–1
24. Patel DR, Gomez GA, Henderson ES, Gamarra M. Primaryprostatic involvement in non-Hodgkin lymphoma. Urology. 1988;32:96–8.
25. George J. et al, The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors. European Urology. 2022;82(5):469-482
26. D.G. Bostwick, K.A. Iczkowski, M.B. Amin, G. Discigil, B. Osborne. Malignant lymphoma involving the prostate: report of 62 cases.Cancer. 1998;83(4):732-738.
27. Kubots Y, Kawai A, Tsuchiya T, Kozima K, Yokoi S, Deguchi T. Bilateral primary malignant lymphoma of the ureter. Int J Clin Oncol. 2007;12:482-484.
28. Farid K, Yahya D, Reza P, Matias K, Heinrich WH. Lymphomas of the female genital tract: A study of 186 cases and review of the literature. Am J Surg Pathol. 2005;29(11):1512-1520.